高级检索
詹智, 张晓春, 侯士强, 等. 白介素31在肺动脉高压患者血浆中的表达及其临床意义[J]. 中国临床医学, 2024, 31(3): 394-401. DOI: 10.12025/j.issn.1008-6358.2024.20240366
引用本文: 詹智, 张晓春, 侯士强, 等. 白介素31在肺动脉高压患者血浆中的表达及其临床意义[J]. 中国临床医学, 2024, 31(3): 394-401. DOI: 10.12025/j.issn.1008-6358.2024.20240366
ZHAN Zhi, ZHANG Xiaochun, HOU Shiqiang, et al. Expression and clinical significance of interleukin-31 in plasma from patients with pulmonary arterial hypertension[J]. Chinese Journal of Clinical Medicine, 2024, 31(3): 394-401. DOI: 10.12025/j.issn.1008-6358.2024.20240366
Citation: ZHAN Zhi, ZHANG Xiaochun, HOU Shiqiang, et al. Expression and clinical significance of interleukin-31 in plasma from patients with pulmonary arterial hypertension[J]. Chinese Journal of Clinical Medicine, 2024, 31(3): 394-401. DOI: 10.12025/j.issn.1008-6358.2024.20240366

白介素31在肺动脉高压患者血浆中的表达及其临床意义

Expression and clinical significance of interleukin-31 in plasma from patients with pulmonary arterial hypertension

  • 摘要:
    目的 探讨肺动脉高压(pulmonary arterial hypertension, PAH)患者血浆中白介素31(interleukin-31, IL-31)的表达水平及其临床相关性。
    方法 选择2021年1月1日至2023年12月30日在复旦大学附属中山医院心血管内科住院并诊断为PAH的患者(PAH组),以及同期健康体检人群(对照组)。收集两组研究对象临床资料及随访结果。采用酶联免疫吸附实验(enzyme-linked immunosorbent assay, ELISA)检测血浆中IL-31、IL-1β、IL-6、IL-10、IL-12p70、单核细胞趋化蛋白1(monocyte chemoattractant protein-1, MCP-1)、肿瘤坏死因子α (tumor necrosis factor-α, TNF-α)和转化生长因子β1(transforming growth factor-β1, TGF-β1)的浓度。采用Pearson相关性检验评价PAH患者IL-31与右心导管参数、心脏超声参数以及血液指标的相关性。采用Cox比例风险模型分析PAH患者预后的影响因素。
    结果 共纳入50例PAH患者及22名健康对照者。两组研究对象的年龄、性别组成、体质量指数和左室射血分数差异无统计学意义。与对照组相比,PAH组血浆IL-31的表达水平升高168.82(149.14, 177.26)pg/mL vs 152.76(145.58, 159.41)pg/mL, P=0.001。Pearson相关性检验
    结果 显示,PAH组患者血浆IL-31的表达水平与肺动脉平均压(r=0.652, P<0.001)及肺血管阻力正相关(r=0.651, P<0.001),与三尖瓣环收缩期位移负相关(r=﹣0.496, P<0.001)。Cox比例风险模型分析显示,血浆IL-31表达增加是PAH患者发生心衰再入院或全因死亡的独立预测因素(HR=1.130, 95%CI 1.052~1.214, P=0.001)。
    结论 PAH患者血浆IL-31的表达水平较健康人群升高,且IL-31升高与PAH的严重程度及预后较差相关。

     

    Abstract:
    Objective To investigate the plasma level of interleukin-31 (IL-31) in patients with pulmonary arterial hypertension (PAH) and its clinical relevance.
    Methods The patients who were diagnosed as PAH in Zhongshan Hospital, Fudan University from January 1, 2021 to December 30, 2023 (PAH group) and the healthy people in the same period (control group) were selected. The clinical data and follow-up records were collected. Plasma levels of IL-31, IL-1β, IL-6, IL-10, IL-12p70, monocyte chemoattractant protein-1 (MCP-1), tumor necrosis factor-α (TNF-α) and transforming growth factor-β1 (TGF-β1) were detected by enzyme-linked immunosorbent assay (ELISA). Pearson correlation test was used to evaluate the correlations between IL-31 and right cardiac catheterization parameters, echocardiography parameters and blood indices in patients with PAH. Cox proportional hazard model was used to analyze the prognostic factors of patients in PAH group.
    Results A total of 50 patients with PAH and 22 healthy controls were included. There was no significant difference in age, gender, body mass index and left ventricular ejection fraction between the two groups. Compared with the control group, the plasma level of IL-31 in the PAH group was significantly higher (168.82 149.14, 177.26 pg/mL vs 152.76 145.58, 159.41 pg/mL, P=0.001). Pearson correlation test showed that the plasma level of IL-31 in PAH patient was positively correlated with mean pulmonary artery pressure (r=0.652, P < 0.001) and pulmonary vascular resistance (r=0.651, P < 0.001), but was negatively correlated with tricuspid annular plane systolic excursion (r=﹣0.496, P < 0.001). Cox proportional hazard model showed that higher plasma level of IL-31 was an independent predictor of readmission for heart failure/all-cause mortality in patients with PAH (HR=1.130, 95%CI 1.052-1.214, P=0.001).
    Conclusions Plasma level of IL-31 may be significantly increased in patients with PAH and be positively correlated with the severity of PAH, and elevated level of IL-31 is predictive of poor prognosis in PAH patients.

     

/

返回文章
返回